Trial of EXenatide in Acute Ischaemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 350 participants.
Also called NCT03287076
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 350 participants
- Sponsor
- Registry
-
NCT03287076 -
2018-004325-88
-
- Other papers using this trial's data
- Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Finland, New Zealand
- Registry status
- Unknown status
Technical summary
Registry record NCT03287076. Randomized; single masking; primary purpose treatment. Start 2017-11-23 (actual); primary completion 2021-10-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial of EXenatide in Acute Ischaemic Stroke
- Acronym
- TEXAIS
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Exenatide Injection
- Lead sponsor
- Neuroscience Trials Australia
- Collaborator
- National Health and Medical Research Council, Australia
- Collaborator
- Monash University
Record details
- Record id
cardio:ct-nct03287076- Content hash
645a0caa8d380d28aec0d63b6eb3ec86b0bab3762fe5c0c069fb897363237ec7